Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells

References

• ZeisbergMNeilsonEGMechanisms of tubulointerstitial fibrosisJ Am Soc Nephrol201021111819183420864689
   PubMed Web of Science ®Google Scholar
• BoorPOstendorfTFloegeJRenal fibrosis: novel insights into mechanisms and therapeutic targetsNat Rev Nephrol201061164365620838416
   PubMed Web of Science ®Google Scholar
• MezzanoSADroguettMABurgosMEOverexpression of chemokines, fibrogenic cytokines, and myofibroblasts in human membranous nephropathyKidney Int200057114715810620196
   PubMed Web of Science ®Google Scholar
• Sean EardleyKCockwellPMacrophages and progressive tubulointerstitial diseaseKidney Int200568243745516014021
   PubMed Web of Science ®Google Scholar
• HewitsonTDRenal tubulointerstitial fibrosis: common but never simpleAm J Physiol Renal Physiol20092966F1239124419144691
   PubMed Web of Science ®Google Scholar
• DolmanMEHarmsenSStormGHenninkWEKokRJDrug targeting to the kidney: Advances in the active targeting of therapeutics to proximal tubular cellsAdv Drug Deliv Rev201062141344135720719242
   PubMed Web of Science ®Google Scholar
• RipleyEComplementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney diseaseAm Heart J20091576 SupplS71619450722
   PubMed Web of Science ®Google Scholar
• YuLNobleNABorderWATherapeutic strategies to halt renal fibrosisCurr Opin Pharmacol20022217718111950630
   PubMed Web of Science ®Google Scholar
• KontovinisLFPapazisisKTTouplikiotiPAndreadisCMouratidouDKortsarisAHSunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markersBMC Cancer200998219284623
   PubMed Web of Science ®Google Scholar
• SablinMPDreyerCColichiCBenefits from pharmacological and pharmacokinetic properties of sunitinib for clinical developmentExpert Opin Drug Metab Toxicol2010681005101520636223
   PubMed Web of Science ®Google Scholar
• LeeWJLeeJLChangSECutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinibBr J Dermatol200916151045105119558553
   PubMed Web of Science ®Google Scholar
• KaramanMWHerrgardSTreiberDKA quantitative analysis of kinase inhibitor selectivityNat Biotechnol200826112713218183025
   PubMed Web of Science ®Google Scholar
• BonnerJCRegulation of PDGF and its receptors in fibrotic diseasesCytokine Growth Factor Rev200415425527315207816
   PubMed Web of Science ®Google Scholar
• TrojanowskaMRole of PDGF in fibrotic diseases and systemic sclerosisRheumatology (Oxford)200847Suppl 5v2v418784131
   PubMed Web of Science ®Google Scholar
• KanellisJPaizisKCoxAJRenal ischemia-reperfusion increases endothelial VEGFR-2 without increasing VEGF or VEGFR-1 expressionKidney Int20026151696170611967019
   PubMed Web of Science ®Google Scholar
• MalmstromNKKallioEARintalaJMVascular endothelial growth factor in chronic rat allograft nephropathyTranspl Immunol200819213614418503889
   PubMed Web of Science ®Google Scholar
• TuguesSFernandez-VaroGMunoz-LuqueJAntiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic ratsHepatology20074661919192617935226
   PubMed Web of Science ®Google Scholar
• ForceTKrauseDSVan EttenRAMolecular mechanisms of cardiotoxicity of tyrosine kinase inhibitionNat Rev Cancer20077533234417457301
   PubMed Web of Science ®Google Scholar
• BovelliDPlataniotisGRoilaFCardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice GuidelinesAnn Oncol201021Suppl 5v277v28220555097
   PubMed Web of Science ®Google Scholar
• Di LorenzoGAutorinoRBruniGCardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysisAnn Oncol20092091535154219474115
   PubMed Web of Science ®Google Scholar
• BhojaniNJeldresCPatardJJToxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinomaEur Urol200853591793018054825
   PubMed Web of Science ®Google Scholar
• RosenbaumSEWuSNewmanMAWestDPKuzelTLacoutureMEDermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinibSupport Care Cancer200816655756618274784
   PubMed Web of Science ®Google Scholar
• PrakashJde BorstMHLacombeMInhibition of renal rho kinase attenuates ischemia/reperfusion-induced injuryJ Am Soc Nephrol200819112086209718650485
   PubMed Web of Science ®Google Scholar
• PrakashJde BorstMHvan Loenen-WeemaesAMCell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosisPharm Res200825102427243918183478
   PubMed Web of Science ®Google Scholar
• PrakashJSandoviciMSalujaVIntracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 [4-(4- fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular cells: a novel strategy to treat renal fibrosisJ Pharmacol Exp Ther2006319181916807361
   PubMed Web of Science ®Google Scholar
• ChristensenEIVerroustPJNielsenRReceptor-mediated endocytosis in renal proximal tubulePflugers Arch200945861039104819499243
   PubMed Web of Science ®Google Scholar
• TemmingKFretzMMKokRJOrgan- and cell-type specific delivery of kinase inhibitors: a novel approach in the development of targeted drugsCurr Mol Pharmacol20081111220021419
   PubMedGoogle Scholar
• GonzaloTBeljaarsLvan de BovenkampMLocal inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cellsJ Pharmacol Exp Ther2007321385686517369283
   PubMed Web of Science ®Google Scholar
• LiuYGrayNSRational design of inhibitors that bind to inactive kinase conformationsNat Chem Biol20062735836416783341
   PubMed Web of Science ®Google Scholar
• LiaoJJMolecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitorsJ Med Chem200750340942417266192
   PubMed Web of Science ®Google Scholar
• GajiwalaKSWuJCChristensenJKIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patientsProc Natl Acad Sci U S A200910651542154719164557
   PubMed Web of Science ®Google Scholar
• HarmsenSDolmanMEMNemesZDevelopment of a cell-selective and intrinsically active multikinase inhibitor bioconjugateBioconjug Chem201122454054521443263
   PubMed Web of Science ®Google Scholar
• SunLLiangCShirazianSDiscovery of 5-[5-fluoro-2-oxo- 1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3- carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinaseJ Med Chem20034671116111912646019
   PubMed Web of Science ®Google Scholar
• van GijlswijkRPTalmanEGPeekelIUse of horseradish peroxidase- and fluorescein-modified cisplatin derivatives for simultaneous labeling of nucleic acids and proteinsClin Chem20024881352135912142394
   PubMed Web of Science ®Google Scholar
• PapazisisKTGeromichalosGDDimitriadisKAKortsarisAHOptimization of the sulforhodamine B colorimetric assayJ Immunol Methods199720821511589433470
   PubMed Web of Science ®Google Scholar
• RippeARippeCSwardKRippeBDisproportionally low clearance of macromolecules from the plasma to the peritoneal cavity in a mouse model of peritoneal dialysisNephrol Dial Transplant2007221889517050632
   PubMed Web of Science ®Google Scholar
• SparidansRWIusufDSchinkelAHSchellensJHBeijnenJHLiquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasmaJ Chromatogr B Analyt Technol Biomed Life Sci20098773240904096
   Web of Science ®Google Scholar
• FretzMMDolmanMELacombeMIntervention in growth factor activated signaling pathways by renally targeted kinase inhibitorsJ Control Release2008132320020718793687
   PubMed Web of Science ®Google Scholar
• TemmingKLacombeMSchaapveldRQRational design of RGD-albumin conjugates for targeted delivery of the VEGF-R kinase inhibitor PTK787 to angiogenic endotheliumChem Med Chem20061111200120316991175
   PubMed Web of Science ®Google Scholar
• DolmanMEvan DorenmalenKMPietersEHImatinib-ULS-lysozyme: A proximal tubular cell-targeted conjugate of imatinib for the treatment of renal diseasesJ Control Release2011 [Epub ahead of print.]10.1016/j.jconrel.2011.08.041
   Web of Science ®Google Scholar
• HulsMBrownCDWindassASThe breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membraneKidney Int200873222022517978814
   PubMed Web of Science ®Google Scholar
• ShuklaSRobeyRWBatesSEAmbudkarSVSunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2Drug Metab Dispos200937235936518971320
   PubMed Web of Science ®Google Scholar
• YangH-CZuoYFogoABModels of chronic kidney diseaseDrug Discov Today Dis Models201071–2131921286234
   PubMedGoogle Scholar
• DemetriGDvan OosteromATGarrettCREfficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialLancet200636895441329133817046465
   PubMed Web of Science ®Google Scholar
• ChungACHuangXRZhouLHeuchelRLaiKNLanHYDisruption of the Smad7 gene promotes renal fibrosis and inflammation in unilateral ureteral obstruction (UUO) in miceNephrol Dial Transplant20092451443145419096081
   PubMed Web of Science ®Google Scholar
• YuanXPHeXSWangCXLiuLSFuQTriptolide attenuates renal interstitial fibrosis in rats with unilateral ureteral obstructionNephrology (Carlton)201116220021021272133
   PubMed Web of Science ®Google Scholar
• PuriTSShakaibMIChangAChronic kidney disease induced in mice by reversible unilateral ureteral obstruction is dependent on genetic backgroundAm J Physiol Renal Physiol20102984F1024103220089676
   PubMed Web of Science ®Google Scholar
• TapmeierTTBrownKLTangZSacksSHSheerinNSWongWReimplantation of the ureter after unilateral ureteral obstruction provides a model that allows functional evaluationKidney Int200873788588918200000
   PubMed Web of Science ®Google Scholar
• LiLEmmettNMannDZhaoXFenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-kappaB and transforming growth factor-beta1/Smad3 in diabetic nephropathyExp Biol Med (Maywood)2010235338339120404057
   PubMed Web of Science ®Google Scholar